Artelo Biosciences AI Stock Analysis
Want to see ARTL full AI Analyst Report?
Artelo Biosciences (ARTL) AI Stock Analysis
Artelo Biosciences
(NASDAQ:ARTL)
The score is driven primarily by weak financial performance (no revenue, multi-year losses, and worsening cash burn), which elevates financing risk. Technicals also weigh on the outlook with price below key moving averages and negative MACD, though near-oversold momentum provides only limited offset. Valuation is constrained by negative earnings (negative P/E), and corporate-event risk is heightened by Nasdaq listing compliance uncertainty.
Artelo Biosciences (ARTL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 476.60K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -0.62
- Revenue Growth
- ―
- EPS Growth
- 81.76%
- Country
- US
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Artelo Biosciences Business Overview & Revenue Model
Company Description
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising...
Artelo Biosciences Financial Statement Overview
Summary
Financials reflect an early-stage, high-risk profile: $0 revenue across all shown periods, recurring sizable net losses (TTM net loss about -$11.3M), and negative/worsening operating and free cash flow (FCF about -$11.8M TTM), indicating an elevated cash-burn and financing need. A key offset is low leverage (about $40K total debt) and positive equity in TTM (~$6.2M), but overall funding sustainability remains the central risk.
Income Statement
12Very NegativeBalance Sheet
48NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -10.81M | -12.54M | -9.83M | -9.29M | -10.08M | -7.44M |
| Net Income | -11.32M | -12.88M | -9.83M | -9.29M | -10.08M | -7.44M |
Balance Sheet | ||||||
| Total Assets | 6.67M | 2.80M | 4.70M | 13.04M | 20.42M | 12.63M |
| Cash, Cash Equivalents and Short-Term Investments | 4.44M | 600.00K | 2.34M | 10.43M | 17.53M | 10.06M |
| Total Debt | 40.00K | 678.00K | 104.00K | 23.00K | 63.00K | 95.00K |
| Total Liabilities | 439.00K | 4.07M | 1.84M | 1.29M | 1.02M | 593.00K |
| Stockholders Equity | 6.24M | -1.27M | 2.86M | 11.75M | 19.40M | 12.04M |
Cash Flow | ||||||
| Free Cash Flow | -11.76M | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Operating Cash Flow | -11.76M | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Investing Cash Flow | 188.00K | -62.00K | 7.77M | 3.51M | 2.96M | -3.44M |
| Financing Cash Flow | 14.26M | 6.87M | 112.00K | 567.00K | 0 | 14.11M |
Artelo Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Negative. The current price of 1.50 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 3.29, and below the 200-day MA of 19.11, indicating a bearish trend. The MACD of -0.41 indicates Negative momentum. The RSI at 28.68 is Positive, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTL.
Artelo Biosciences Risk Analysis
Artelo Biosciences disclosed 56 risk factors in its most recent earnings report. Artelo Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksArtelo Biosciences Peers Comparison
Overall Rating
ENVB47Neutral
INDP47Neutral
TOVX42Neutral
ARTL41Neutral
BDRX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $6.36M | -0.23 | -163.22% | ― | ― | 93.45% | |
| 47Neutral | $509.96M | -0.82 | -206.82% | ― | ― | 87.31% | |
| 42Neutral | $6.61M | -0.57 | -64.99% | ― | ― | 95.48% | |
| 41Neutral | $1.57M | -0.02 | -272.21% | ― | ― | 81.76% | |
| 40Underperform | $1.07M | -38.71 | -42.42% | ― | ― | 97.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARTL | Artelo Biosciences | 1.50 | -44.67 | -96.75% | |
| BDRX | Biodexa Pharmaceuticals Plc | 2.04 | -155.16 | -98.71% | |
| TOVX | Theriva Biologics, Inc. | 0.14 | -0.07 | -32.71% | |
| INDP | Indaptus Therapeutics, Inc. | 3.29 | 1.54 | 88.00% | |
| ENVB | Enveric Biosciences, Inc. | 1.42 | -4.43 | -75.73% |
Artelo Biosciences Corporate Events
Artelo Biosciences Addresses Nasdaq Listing Compliance Uncertainty
NegativeOn July 22, 2026, the SEC approved Nasdaq’s new $5,000,000 market value of listed securities rule, which exposes companies below that threshold, including Artelo Biosciences, to potential delisting unless they regain compliance. The rule was temporar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
